

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
390069.401APPLICATION NO.
10/053,530

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Jeffrey A. Ledbetter et al.FILING DATE
January 17, 2002GROUP ART UNIT
1644 #7

Sheet 1 of 6

JUL 15 2002
TECH CENTER 1600/2900

RECEIVED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LA	AA	4,704,692	11/03/87	Ladner	364	496	
	AB	4,816,567	03/28/89	Cabilly et al.	530	387	
	AC	4,906,562	03/06/90	Hellstrom et al.	435	7	
	AD	4,935,495	06/19/90	Hellström et al.	530	387	
	AE	4,946,778	08/07/90	Ladner et al.	435	69.6	
	AF	5,091,177	02/25/92	Hellström et al.	424	85.8	
	AG	5,225,539	07/06/93	Winter	530	387.3	
LA	AH	5,500,362	03/19/96	Robinson et al.	455	723	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
LA	AI	WO 89/07142	08/10/89	WIPO		
	AJ					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LA	AK	Batra et al., "Single-Chain Immunotoxins Directed at the Human Transferrin Receptor Containing <i>Pseudomonas</i> Exotoxin A or Diphtheria Toxin: Anti-TFR(Fv)-PE40 and DT388-Anti-TFR(Fv)," <i>Molecular and Cellular Biology</i> 11(4):2200-2205, April 1991.
	AL	Beiske et al., "Triggering of Neoplastic B Cells Via Surface IgM and the Cell Surface Antigens CD20 and CDw40. Responses Differ from Normal Blood B Cells and are Restricted to Certain Morphologic Subsets," <i>Int. J. Cancer</i> 42:521-528, 1988.
	AM	Brown et al., "Treatment of B-Cell Lymphomas With Anti-idiotypic Antibodies Alone and in Combination With Alpha Interferon," <i>Blood</i> 73(3):651-661, February 15, 1989.
	AN	Chaudhary et al., "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin," <i>Nature</i> 339:394-397, June 1, 1989.
LA	AO	Clark et al., "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50," <i>Proc. Natl. Acad. Sci. USA</i> 83:4494-4498, June 1986.

EXAMINER

DATE CONSIDERED 3/26/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
390069.401APPLICATION NO.
10/053,530

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jeffrey A. Ledbetter et al.

FILING DATE

January 17, 2002

GROUP ART UNIT

1644

 RECEIVED
 JUL 15 2002
 TECH CENTER 1600/290

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LA	BA	5,530,101	06/25/96	Queen et al.	530	387.3	
	BB	5,585,089	12/17/96	Queen et al.	424	13.1	
	BC	5,597,707	01/28/97	Marken et al.	435	69.3	
	BD	5,645,835	07/08/97	Fell, Jr. et al.	424	134.1	
	BE	5,693,762	12/02/97	Queen et al.	530	387.3	
	BF	5,795,572	08/18/98	Diegel et al.	424	135.1	
	BG	5,807,734	09/15/98	Diegel et al.	435	252.33	
LA	BH	5,869,620	02/09/99	Whitlow et al.	530	387.3	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LA	BI	Davis et al., "High Level Expression in Chinese Hamster Ovary Cells of Soluble Forms of CD4 T Lymphocyte Glycoprotein Including Glycosylation Variants," <i>The Journal of Biological Chemistry</i> 265(18):10410-10418, June 25, 1990.
	BJ	Dillman et al., "Continuous Infusion of T101 Monoclonal Antibody in Chronic Lymphocytic Leukemia and Cutaneous T-Cell Lymphoma," <i>Journal of Biological Response Modifiers</i> 5(5):394-410, 1986.
	BK	Einfeld et al., "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains," <i>EMBO Journal</i> 7:711-717, 1988.
	BL	Funakoshi et al., "Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas," <i>Journal of Immunotherapy</i> 19(2):93-101, 1996.
	BM	Funakoshi et al., "Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation," <i>Blood</i> 83(10):2787-2794, May 15, 1994.
LA	BN	Hekman et al., "Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody," <i>Cancer Immunol. Immunother.</i> 32:364-372, 1991.

EXAMINER

DATE CONSIDERED

3/26/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 390069.401	APPLICATION NO. 10/053,530
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Jeffrey A. Ledbetter et al.	
		FILING DATE January 17, 2002	GROUP ART UNIT 1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LB	CA	5,876,950	03/02/99	Siadak et al.	435	7.23	
LB	CB	5,888,773	03/30/99	Jost et al.	435	69.6	
LB	CC	5,892,019	04/06/99	Schlom et al.	536	23.53	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LA	CD	Hollenbaugh et al., "The Human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity," <i>EMBO Journal</i> 11:4313-4321, 1992.
	CE	Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 85:5879-5883, August 1988.
	CF	Jost et al., "Mammalian Expression and Secretion of Functional Single-chain Fv Molecules," <i>The Journal of Biological Chemistry</i> 269(42):26267-26273, October 21, 1994.
	CG	Kaminski et al., "Radioimmunotherapy of B-Cell Lymphoma with [¹³¹ I] Anti-B1 (Anti-CD20) Antibody," <i>The New England Journal of Medicine</i> 329(7):459-465, August 12, 1993.
	CH	Kato et al., "A conformational change in the Fc precludes the binding of two Fcγ receptor molecules to one IgG," <i>Immunology Today</i> 21(7):310-312, July 2000.
	CI	Koolwijk et al., "Interaction Between Hybrid Mouse Monoclonal Antibodies and the Human High-Affinity IgG FcR, huFcγRI, on U937," <i>The Journal of Immunology</i> 143(5):1656-1662, September 1, 1989.
	CJ	Ledbetter et al., "Augmentation of Normal and Malignant B Cell Proliferation by Monoclonal Antibody to the B Cell-Specific Antigen BP50 (CDW40)," <i>The Journal of Immunology</i> 138(3):788-794, February 1, 1987.
	CK	Liu et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity," <i>The Journal of Immunology</i> 139(10):3521-3526, November 15, 1987.

EXAMINER	DATE CONSIDERED 3/26/03
----------	-------------------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



FORM PTO-1449
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
390069.401

APPLICATION NO.
10/053,530

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jeffrey A. Ledbetter et al.

FILING DATE

January 17, 2002

GROUP ART UNIT

1644

Sheet 4 of 6

JUL 15 2002
TECH CENTER 1600/2900

RECEIVED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
			YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


LA	DA	Maloney et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients With Relapsed Non-Hodgkin's Lymphoma," <i>Journal of Clinical Oncology</i> 15(10):3266-3274, October 1997.
	DB	Maloney et al., "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma," <i>Blood</i> 90(6):2188-2195, September 15, 1997.
	DC	McLaughlin et al., "IDEC-C2B8 ANTI-CD20 Antibody: Final Report on a Phase III Pivotal Trial in Patients (PTS) With Relapsed Low-Grade or Follicular Lymphoma (LG/F NHL)," <i>Blood</i> 88(Abstract Suppl. 1):90a, Abstract 349, 1996.
	DD	Pawson et al., "Treatment of T-Cell Prolymphocytic Leukemia With Human CD52 Antibody," <i>Journal of Clinical Oncology</i> 15(7):2667-2672, July 1997.
	DE	Press et al., "Monoclonal Antibody 1F5 (Anti-CD20) Serotherapy of Human B Cell Lymphomas," <i>Blood</i> 69(2):584-591, February 1987.
	DF	Press et al., "Radiolabeled-Antibody Therapy of B-Cell Lymphoma With Autologous Bone Marrow Support," <i>The New England Journal of Medicine</i> 329(17):1219-1224, October 21, 1993.
	DG	Radaev et al., "The Structure of a Human Type III Fcγ Receptor in Complex with Fc," <i>The Journal of Biological Chemistry</i> 276(19):16469-16477, May 11, 2001.
	DH	Radaev and Sun, "Recognition of IgG by Fcγ Receptor," <i>The Journal of Biological Chemistry</i> 276(19):16478-16483, May 11, 2001.
	DI	Scheinberg et al., "A Phase I Toxicity, Pharmacology, and Dosimetry Trial of Monoclonal Antibody OKB7 in Patients With Non-Hodgkin's Lymphoma: Effects of Tumor Burden and Antigen Expression," <i>Journal of Clinical Oncology</i> 8(5):792-803, May 1990.
	DJ	Sensel et al., "Engineering Novel Antibody Molecules," <i>Chemical Immunology</i> 65: 129-158, 1997.
LS	DK	Shan et al., "Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies," <i>Blood</i> 91(5):1644-1652, March 1, 1998.

EXAMINER

DATE CONSIDERED

3/26/07

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
390069.401APPLICATION NO.
10/053,530

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jeffrey A. Ledbetter et al.

FILING DATE

January 17, 2002

GROUP ART UNIT

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
			YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EA	Shan et al., "Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths," <i>The Journal of Immunology</i> 162(11):6589-6595, June 1, 1999.
EB	Shin et al., "Hybrid Antibodies," <i>Intern. Rev. Immunol.</i> 10:177-186, 1993.
EC	Shin et al., "Genetically-Engineered Antibodies: Tools for the Study of Diverse Properties of the Antibody Molecule," <i>Immunological Reviews</i> 130:87-107, 1992.
ED	Sondermann et al., "The 3.2-Å crystal structure of the human IgG1 fragment-FcγRIII complex," <i>Nature</i> 406:267-273, July 20, 2000.
EE	Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>EMBO Journal</i> 10:3655-3659, 1991.
EF	Vlasveld et al., "Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19," <i>Cancer Immunol. Immunother.</i> 40:37-47, 1995.
EG	White et al., "Activation of Dense Human Tonsillar B Cells. Induction of <i>c-myc</i> Gene Expression via Two Distinct Signal Transduction Pathways," <i>The Journal of Immunology</i> 146(3):846-859, February 1, 1993.
EH	Yokota et al., "Rapid Tumor Penetration of a Single-Chain Fv and Comparison with Other Immunoglobulin Forms," <i>Cancer Research</i> 52:3402-3408, June 15, 1992.
EI	Genbank Accession No. L07414, April 27, 1993.
EJ	Genbank Accession No. M62541, July 26, 1993.
EK	Genbank Accession No. M62542, April 27, 1993.
EL	Genbank Accession No. M83312, September 23, 1996.
EM	Genbank Accession No. M84371, July 17, 1995.
EN	Genbank Accession No. U15637, March 8, 2002.

EXAMINER

DATE CONSIDERED 3/26/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)

JUL 12 2002

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
390069.401APPLICATION
10/053,536

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jeffrey A. Ledbetter et al.

FILING DATE

January 17, 2002

GROUP ART UNIT

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						
	FB						
	FC						
	FD						
	FE						
	FF						
	FG						
	FH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	FI					
	FJ					
	FK					
	FL					
	FM					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

60	FN	Genbank Accession No. X14046, September 12, 1993.
	FO	Genbank Accession No. X53517, February 17, 1992.
	FP	Genbank Accession No. X65453, April 26, 2001.
	FQ	Genbank Accession No. X67878, June 6, 1997.
	FR	Genbank Accession No. X96710, February 13, 1997.
NA	FS	Genbank Accession No. Y10507, September 4, 1997.
	FT	

EXAMINER

DATE CONSIDERED

3/24/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).